AR044660A1 - Composiciones farmaceuticas de atorvastatina - Google Patents
Composiciones farmaceuticas de atorvastatinaInfo
- Publication number
- AR044660A1 AR044660A1 ARP040102009A ARP040102009A AR044660A1 AR 044660 A1 AR044660 A1 AR 044660A1 AR P040102009 A ARP040102009 A AR P040102009A AR P040102009 A ARP040102009 A AR P040102009A AR 044660 A1 AR044660 A1 AR 044660A1
- Authority
- AR
- Argentina
- Prior art keywords
- atorvastatin
- pharmaceutical composition
- pharmaceutical compositions
- compositions
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición farmacéutica granulada en seco que comprende atorvastatina o una sal farmacéuticamente aceptable de la misma, así como una composición farmacéutica granulada en seco que comprende atorvastatina o una sal farmacéuticamente aceptable de la misma en combinación con al menos otro fármaco activo, los procedimientos para preparar tales composiciones, kits para contener tales composiciones, y un procedimiento para tratar hipercolesterolemia y/o hiperlipidemia, osteoporosis, hiperplasia prostática benigna (BPH) y enfermedad de Alzheimer usando una cantidad terapéuticamente eficaz de la composición farmacéutica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47791703P | 2003-06-12 | 2003-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR044660A1 true AR044660A1 (es) | 2005-09-21 |
Family
ID=33551780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040102009A AR044660A1 (es) | 2003-06-12 | 2004-06-10 | Composiciones farmaceuticas de atorvastatina |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1635788A1 (es) |
JP (1) | JP2006527259A (es) |
KR (1) | KR100760112B1 (es) |
CN (1) | CN1805732A (es) |
AR (1) | AR044660A1 (es) |
AU (1) | AU2004246867A1 (es) |
BR (1) | BRPI0411354A (es) |
CA (1) | CA2465693A1 (es) |
CO (1) | CO5640071A2 (es) |
MX (1) | MXPA05012955A (es) |
NO (1) | NO20060149L (es) |
RU (1) | RU2325903C2 (es) |
TW (1) | TW200503689A (es) |
WO (1) | WO2004110406A1 (es) |
ZA (1) | ZA200508204B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200630335A (en) * | 2004-10-18 | 2006-09-01 | Teva Pharma | Processes for preparing amorphous atorvastatin hemi-calcium |
CA2547216A1 (en) * | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
US8124622B2 (en) | 2006-03-29 | 2012-02-28 | Kowa Co., Ltd. | Triglyceride-lowering agent and hyperinsulinism-ameliorating agent |
CN101973922B (zh) * | 2009-05-27 | 2013-01-23 | 天津和美生物技术有限公司 | 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用 |
US10071059B2 (en) | 2009-12-18 | 2018-09-11 | Frieslandcampina Nederland Holding B.V. | Co-processed tablet excipient composition its preparation and use |
CA2784996A1 (en) * | 2009-12-22 | 2011-06-30 | Novartis Ag | Formulation comprising 1 h-quinazoline-2,4-dione ampa receptor antagonists, in the form of immediate release tablets and preparation thereof |
EP2575757A1 (en) | 2010-06-03 | 2013-04-10 | Mahmut Bilgic | Water soluble formulation comprising a combination of amlodipine and a statin |
EA018867B1 (ru) * | 2012-11-01 | 2013-11-29 | Лаборатория Тютор С.А.С.И.Ф.И.А. | Способ получения фармацевтической композиции и продукт способа |
CN104825449A (zh) * | 2014-02-12 | 2015-08-12 | 天津药物研究院 | 含有阿托伐他汀钙和氨氯地平的复方组合物及其制备方法 |
CN107111055B (zh) * | 2014-09-26 | 2020-02-21 | 株式会社藤仓 | 光纤 |
RU2591079C2 (ru) * | 2014-12-10 | 2016-07-10 | Александр Владимирович Диковский | Фармацевтическая композиция статинов с пребиотиком для терапии гиперхолестеринемии и гиперлипидимии |
RU2702740C2 (ru) * | 2015-06-10 | 2019-10-10 | Эвоник Рём ГмбХ | Способ получения порошка, содержащего белок, представляющий собой фактор свертывания крови человека, и полимер на основе молочной кислоты |
CN106580908A (zh) * | 2015-10-16 | 2017-04-26 | 深圳信立泰药业股份有限公司 | 一种用于心血管疾病治疗的口服制剂及其制备方法 |
WO2023025672A1 (en) | 2021-08-25 | 2023-03-02 | Basf Se | Direct tableting auxiliary composition |
CN114674944A (zh) * | 2022-03-04 | 2022-06-28 | 苏州东瑞制药有限公司 | 一种检测苯磺酸氨氯地平与阿托伐他汀钙复方制剂有关物质的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL355805A1 (en) * | 1999-11-17 | 2004-05-17 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
SI20848A (sl) | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
MXPA03008837A (es) * | 2001-03-27 | 2004-05-05 | Ranbaxy Lab Ltd | Una composicion farmaceutica estable de pravastatina. |
JP2003055217A (ja) * | 2001-08-10 | 2003-02-26 | Taiyo Yakuhin Kogyo Kk | 医薬組成物 |
GB0121436D0 (en) * | 2001-09-04 | 2001-10-24 | Pfizer Ltd | Biomodulated multiparticulate formulations |
CA2385529A1 (en) * | 2002-05-21 | 2003-11-21 | Bernard Charles Sherman | Stable dosage forms comprising atorvastatin calcium |
CA2508840A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
-
2004
- 2004-04-29 CA CA002465693A patent/CA2465693A1/en not_active Abandoned
- 2004-06-01 CN CNA200480016386XA patent/CN1805732A/zh active Pending
- 2004-06-01 AU AU2004246867A patent/AU2004246867A1/en not_active Abandoned
- 2004-06-01 EP EP04735617A patent/EP1635788A1/en not_active Withdrawn
- 2004-06-01 RU RU2005136743/15A patent/RU2325903C2/ru not_active IP Right Cessation
- 2004-06-01 KR KR1020057023718A patent/KR100760112B1/ko not_active IP Right Cessation
- 2004-06-01 JP JP2006516511A patent/JP2006527259A/ja active Pending
- 2004-06-01 MX MXPA05012955A patent/MXPA05012955A/es unknown
- 2004-06-01 WO PCT/IB2004/001859 patent/WO2004110406A1/en active Application Filing
- 2004-06-01 BR BRPI0411354-3A patent/BRPI0411354A/pt not_active IP Right Cessation
- 2004-06-09 TW TW093116574A patent/TW200503689A/zh unknown
- 2004-06-10 AR ARP040102009A patent/AR044660A1/es unknown
-
2005
- 2005-10-11 ZA ZA200508204A patent/ZA200508204B/xx unknown
- 2005-12-07 CO CO05124314A patent/CO5640071A2/es unknown
-
2006
- 2006-01-10 NO NO20060149A patent/NO20060149L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20060149L (no) | 2006-03-06 |
KR20060025167A (ko) | 2006-03-20 |
CN1805732A (zh) | 2006-07-19 |
CO5640071A2 (es) | 2006-05-31 |
CA2465693A1 (en) | 2004-12-12 |
WO2004110406A1 (en) | 2004-12-23 |
JP2006527259A (ja) | 2006-11-30 |
RU2005136743A (ru) | 2006-07-27 |
KR100760112B1 (ko) | 2007-09-18 |
EP1635788A1 (en) | 2006-03-22 |
BRPI0411354A (pt) | 2006-07-11 |
ZA200508204B (en) | 2007-03-28 |
TW200503689A (en) | 2005-02-01 |
MXPA05012955A (es) | 2006-02-13 |
AU2004246867A1 (en) | 2004-12-23 |
RU2325903C2 (ru) | 2008-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20060149L (no) | Farmasoytiske forbindelser av atorvastatin | |
AR044775A1 (es) | Composiciones farmaceuticas de atorvastatina | |
DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
ATE360630T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
TR200100931T2 (tr) | Yeni sürekli salınımlı oral formülasyonlar | |
UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
DE60114994D1 (de) | Blutplättchen-adp-rezeptor-inhibitoren | |
PE20061091A1 (es) | FORMA CRISTALINA BETA-d DEL CLORHIDRATO DE IVABRANDINA, SU PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN | |
AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
BRPI0607897A2 (pt) | compostos oxindol e sua utilização como agentes terapêuticos | |
NO20061640L (no) | Hurtig opplosningspreparat av en kalsiumreseptiraktiv forbindelse | |
NO20064347L (no) | Substituerte 1,2,3,4-tetrahydroisokinolinderivater | |
TW200510375A (en) | New compounds | |
NO20093464L (no) | Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika | |
NO20060022L (no) | Stabile sammensetninger av atorvastatin fremstilt ved vat granulering | |
SE9900961D0 (sv) | Novel compounds | |
IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
SE9802208D0 (sv) | Novel compounds | |
DE60031686D1 (de) | Pyrazinone, diese verbindungen enthaltende zusammenstellungen | |
AR014640A1 (es) | UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE. | |
BR9811348A (pt) | Compostos derivados de indol, processo para preparação dos mesmos, e, composições farmacêuticas. | |
SE9802209D0 (sv) | Novel compounds | |
TR200200683T2 (tr) | Oral kontrollü salıverme formülasyonları. | |
SE0000303D0 (sv) | Novel compounds | |
EA200500175A1 (ru) | Соль морфин-6-глюкуронида |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |